Progress towards Elimination of HIV Mother-to-Child Transmission in the Dominican Republic from 1999 to 2011
Table 2
HIV mother-to-child transmission risk in the 1999–2008 and 2009–2011 periods, by prenatal antiretroviral, delivery route, and infant feeding prevention strategies, Dominican Republic.
All perinatally exposed
142/1,274 (11.1%)
12/302 (4.0%)*
Any maternal antiretrovirals
54/861 (6.3)
10/267 (3.7)
HAART1 all
4/157 (2.5)
5/174 (2.9)
AZT + 3TC + NVP2
4/157 (2.5)
0/59
AZT + 3TC + Lopinavir/r3
—
5/115 (4.3)
Non-HAART multidose
4/80 (5.0)
—
AZT-containing regimen
Single-dose NVP ALL
32/506 (6.3)
3/60 (5.0)
8 hours precaesarean
25/395 (6.3)
0/2
Labor onset
5/78 (6.4)
—
At delivery
2/30 (6.7)
—
Unspecified
—
3/58 (5.2)
Unknown
14/211 (11.6)
2/30 (6.7)
None
88/413 (21.3)†
2/35 (5.7)*
Delivery
Vaginal
68/285 (23.9)†
6/80 (7.5)*
Caesarean
60/882 (6.8)
5/199 (2.5)*
Unknown
14/107 (13.1)
1/23 (4.3)*
Infant antiretrovirals
Single-dose Nevirapine (SD NVP)
48/782 (6.1)
1/41 (2.4)
SD-NVP after 72 hours
1/13 (7.6)
—
Zidovudine for six weeks
7/139 (5.0)
7/126 (5.6)
Unknown/other/none
32/340 (9.4)†
4/135 (3.0)
Infant feeding
Breast fed only
25/67 (37.3)
0/2
Mixed
16/43 (37.2)
0/4
Formula only
79/972 (8.1)†
11/271 (4.1)*
Unknown
22/192 (11.5)
1/25 (4.0)*
*
P < .05, comparison by time period, 1999–2008 versus 2009–2011. †P < .01 within period, by strategy.
1Highly active antiretroviral therapy.
2AZT-3TC-NVP: zidovudine, lamivudine, nevirapine.
3AZT-3TC-Lop/r: zidovudine, lamivudine, lopinavir (ritonavir boosted).
